Last reviewed · How we verify
recombinant subunit Herpes zoster vaccine
A recombinant subunit vaccine that stimulates the immune system to recognize and prevent herpes zoster (shingles) infection by presenting viral antigens without live virus.
A recombinant subunit vaccine that stimulates the immune system to recognize and prevent herpes zoster (shingles) infection by presenting viral antigens without live virus. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults.
At a glance
| Generic name | recombinant subunit Herpes zoster vaccine |
|---|---|
| Also known as | Shingrix |
| Sponsor | University Health Network, Toronto |
| Drug class | Recombinant subunit vaccine |
| Target | Varicella-zoster virus glycoprotein E (gE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant varicella-zoster virus (VZV) glycoprotein E (gE) combined with an adjuvant system (AS01B) that enhances immune response. This approach triggers both cellular and humoral immunity against VZV without the risks associated with live attenuated vaccines, providing durable protection against herpes zoster and post-herpetic neuralgia in older adults and immunocompromised populations.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of herpes zoster in immunocompromised adults
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
- Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab (PHASE4)
- A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults (PHASE3)
- Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT (PHASE4)
- Solid Organ Transplant SHINGRIX
- A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults (PHASE3)
- Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents (EARLY_PHASE1)
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: